
Opinion|Videos|September 6, 2024
Addressing Unmet Needs and Emerging Agents
Jonathan Silverberg, MD, PhD, MPH, evaluates persistent unmet needs in the field and highlights promising new treatments currently under development.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Despite the available treatment options, what are the remaining unmet needs or areas requiring further research and development in the management of disease states driven by type 2 inflammation?
- What emerging agents in the pipeline are you most excited for?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
2
Patients Face New Care Complexities as DTC Options Expand
3
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
4
Louisiana Delivers Innovative Cancer Treatments, but Ensuring Access Is a Work in Progress
5
















































